Cipla Expands Fall River Operations in USA, Announces Upcoming Hiring for Various Roles

FALL RIVER, Mass., Aug. 7, 2025 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and hereafter referred to as "Cipla" today announced a significant expansion of its manufacturing facility located at Innovation Way in Fall River, Massachusetts. This expansion includes an 83,000-square-foot addition to the existing facility, aimed at increasing production capacity and enhancing operational efficiency. Cipla is expanding its US manufacturing footprint by investing in capacity expansion for complex respiratory products at its advanced facilities in Fall River, MA & Central Islip, Long Island NY.

The new facility will feature state-of-the-art technology and advanced manufacturing processes, ensuring the highest standards of quality and efficiency. Cipla's facility is dedicated to the production of respiratory products for the US market. This facility possesses comprehensive filling capabilities, stringent quality assurance processes, and a specialized workforce trained in complex manufacturing. These capabilities highlight Cipla's commitment to delivering high-quality respiratory care solutions and serving patients across the country.

Marc Falkin, CEO, Cipla North America, said, "This expansion not only underscores our commitment to manufacturing generic pharmaceuticals in the US market, but also reflects our dedication to supporting the community through job creation and economic development."

Employing over 800 individuals in the US, Cipla remains dedicated to meeting the evolving Generic pharmaceutical needs of patients in the US. Cipla was also selected as an awardee by Massachusetts Life Sciences Center (MLSC) in the latest round of the MLSC Tax Incentive Program and will receive tax incentive to support their expansion in Fall River, creating new jobs in the region. Recognized as a 'Great Place To Work' for three years in a row, Cipla USA is now actively hiring for various positions, including roles in manufacturing, quality control, engineering, and operations and will be hosting on the spot interviews in the coming weeks.

Additional information: Interested candidates can visit Cipla's careers page at www.cipla.com to explore available positions and apply online.

For more information, please contact: Stephanie Quinones ([email protected]).

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets. For nearly nine decades, making a difference to patients has inspired every aspect of Cipla's work. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. Cipla is a respiratory leader, ranking #2 in inhaler sales globally and in the top 3 for US generic respiratory sales (within Metered Dose Inhaler and Respule category - IQVIA TRx data as of May 2025). For more information about Cipla and its commitment to respiratory health, please visit Cipla's USA website at www.ciplausa.com .

Logo: https://mma.prnewswire.com/media/947146/1865863/Cipla_Logo.jpg

SOURCE Cipla USA Inc.